Xencor, Inc. (XNCR) Lowered to Sell at BidaskClub
BidaskClub lowered shares of Xencor, Inc. (NASDAQ:XNCR) from a hold rating to a sell rating in a research note released on Monday morning.
A number of other equities analysts have also weighed in on XNCR. Canaccord Genuity reissued a buy rating and issued a $36.00 price objective on shares of Xencor in a research report on Tuesday, August 8th. Zacks Investment Research lowered shares of Xencor from a hold rating to a sell rating in a research report on Friday. Finally, Wedbush reissued an outperform rating and issued a $29.00 price objective on shares of Xencor in a research report on Friday, June 16th. Two equities research analysts have rated the stock with a sell rating, three have given a hold rating and four have issued a buy rating to the company’s stock. Xencor currently has an average rating of Hold and a consensus price target of $29.33.
Xencor (NASDAQ XNCR) traded up 0.5668% during mid-day trading on Monday, hitting $21.7526. 41,949 shares of the stock traded hands. Xencor has a 12-month low of $18.45 and a 12-month high of $29.38. The company’s market cap is $1.02 billion. The firm’s 50-day moving average is $22.61 and its 200-day moving average is $23.06.
Xencor (NASDAQ:XNCR) last posted its quarterly earnings data on Monday, August 7th. The biopharmaceutical company reported ($0.15) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.25) by $0.10. The business had revenue of $13.34 million during the quarter, compared to analyst estimates of $8.15 million. Xencor had a negative net margin of 121.04% and a negative return on equity of 13.79%. Equities research analysts expect that Xencor will post ($1.17) EPS for the current year.
In related news, major shareholder John S. Stafford III purchased 1,500 shares of the company’s stock in a transaction that occurred on Friday, June 16th. The stock was purchased at an average price of $19.67 per share, with a total value of $29,505.00. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Bruce L. A. Carter sold 12,400 shares of the company’s stock in a transaction that occurred on Friday, May 26th. The stock was sold at an average price of $22.19, for a total transaction of $275,156.00. Following the transaction, the director now directly owns 83,344 shares of the company’s stock, valued at approximately $1,849,403.36. The disclosure for this sale can be found here. In the last ninety days, insiders have purchased 34,500 shares of company stock valued at $719,655 and have sold 34,766 shares valued at $739,408. Corporate insiders own 4.14% of the company’s stock.
A number of institutional investors have recently modified their holdings of XNCR. Equitec Specialists LLC bought a new position in shares of Xencor during the second quarter valued at approximately $116,000. SG Americas Securities LLC raised its position in shares of Xencor by 62.6% in the second quarter. SG Americas Securities LLC now owns 8,447 shares of the biopharmaceutical company’s stock valued at $178,000 after buying an additional 3,252 shares during the period. Legal & General Group Plc raised its position in shares of Xencor by 4.5% in the second quarter. Legal & General Group Plc now owns 8,978 shares of the biopharmaceutical company’s stock valued at $189,000 after buying an additional 385 shares during the period. Airain ltd bought a new position in shares of Xencor during the first quarter valued at approximately $213,000. Finally, Citadel Advisors LLC bought a new position in shares of Xencor during the second quarter valued at approximately $224,000. 73.53% of the stock is owned by hedge funds and other institutional investors.
Xencor Company Profile
Xencor, Inc is a clinical-stage biopharmaceutical company. The Company is focused on discovering and developing engineered monoclonal antibodies to treat severe and life threatening diseases. It has developed two clinical-stage product candidates, using its Immune Inhibitor Fc platform: XmAb5871, which is in two Phase II trials and is being developed for autoimmune disease, and XmAb7195, which is in a Phase I trial and is being developed for asthma and allergic diseases.
Receive News & Stock Ratings for Xencor Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Xencor Inc. and related stocks with our FREE daily email newsletter.